Sosei heptares' oral, selective m4 receptor agonist advancing into phase 2 clinical development under multi-program collaboration with neurocrine biosciences

Tokyo and cambridge, united kingdom, aug. 05, 2022 (globe newswire) -- sosei group corporation (“the company”; tse: 4565), the world leader in g protein-coupled receptor (gpcr) focused structure-based drug design (sbdd) and development, has been notified by its partner neurocrine biosciences inc. (“neurocrine”; nasdaq: nbix) that the u.s. food and drug administration (fda) investigational new drug (ind) application for a phase 2 clinical trial of nbi-1117568 for the treatment of schizophrenia has been accepted by the fda and that the study may proceed. the achievement of this important clinical development milestone triggers a $30 million payment to sosei heptares from neurocrine.
NBIX Ratings Summary
NBIX Quant Ranking